INTRODUCTION
Every research study has the potential to cause injury. The Indian Council of Medical Research (ICMR) National Guidelines stipulate that injured participants will receive free treatment for the management of study-related injury and would also be compensated for such injuries. [1] These guidelines state that the sponsor should agree, before research begins, in an a priori agreement, to provide compensation for any physical or psychological injury, and delineates a procedure to decide on the issue of providing compensation on a case-by-case basis. The draft guidelines posted on the ICMR website provide additional details on how this has to be ensured. [2] It has been noted that stake-holders involved in research in India, namely, investigators, sponsors, and Ethics Committee members are not always well-informed regarding these issues. [3] Hence, we decided to conduct a study to determine the extent to which compensation for study-related injury and for the treatment of such an injury are addressed in initial submissions to Ethics Committees so as to identify the points for training of the stake-holders.
MATERIAL AND METHODS
The Informed Consent Documents (ICDs) of research projects submitted in 2007 and 2008 were reviewed. These ICDs had been submitted to the Independent Ethics Committee, Mumbai and the Ethics Committee for Research in Human Subjects (ECRHS), an institutional Ethics Committee of Seth GS Medical College and KEM Hospital, Mumbai for initial review. The research trials were classified as being pharmaceutical industrysponsored, government-sponsored, and investigator-initiated. The statements related to compensation for treatment of study-related injury and compensation for study-related injury in these documents were scrutinized for the following:
[A] Management of study-related injury:
• Presence of statement(s) regarding compensation for treatment of studyrelated injury • Statement(s) for providing free treatment for study-related injury • P r e s e n c e o f c a v e a t s : i m p r o p e r enrollment, investigator negligence, particular arm of the study, whether procedures were to be covered, free treatment only for situations not covered by personal insurance or government programs [B] Compensation for study-related injury:
• Presence of any statement for providing compensation for study-related injury • Statement(s) that there would be no such compensation available • Presence of any caveats or exclusions
The proportion of protocols providing free treatment and compensation for researchrelated injury was presented as percentage. The caveats, exclusions, and conditions, if any, for accessing these were also noted, and their implications for the study participants examined.
RESULTS
The ICDs of 138 protocols were accessed including 115 (83.33%) industry-sponsored, 20 (14.49%) government-sponsored, and three (2.17%) investigator-initiated projects. As stated in Table 1 , only 46 (33.33%) gave an unequivocal statement that free treatment would be provided in case of a trial-related injury. As many as 42 (30.43%) projects did not state anything about providing treatment for a trialrelated injury, whereas several others included statements that indicated certain restrictions.
Where compensation for trial-related injury was concerned, 33 (23.91%) had statements clearly indicating that there would be no provision for compensation whereas 65 (47.10%) ICDs stated nothing on the issue. Several ICDs imposed caveats while providing treatment for injury and hence, statements such as, 'costs of injury not covered by personal insurance or government program would be reimbursed' appeared in the reviewed documents. Ambiguous statements such as, 'treatment will be provided in case of trial-related injury,' or 'treatment will be provided as per insurance' also appeared in the documents. The Þ rst statement does not state who will bear the cost of treatment and the latter does not provide any details. Restrictions such as providing treatment and/or compensation for trial-related injury only to participants in the active drug arm or only if the study would be done as per protocol were also noted. There were ICDs that averred that free treatment or compensation would be provided only if the study would be properly conducted, conducted as per protocol, if the investigator(s) had not erred, or if there had been no negligence on the part of investigating team. Tables 2 and 3 provide salient examples 
DISCUSSION
The study shows that a large proportion of ICDs submitted with protocols for initial review to Ethics Committees do not conform to National Guidelines, nor do they adequately protect the interests of the participants. This could partly be due to ignorance about these issues among sponsors and investigators. This, however, puts onerous responsibilities on the shoulders of the members of Ethics Committees. They need to be aware of the implications of the way the twin issues of providing treatment and providing compensation are currently being handled [ Tables 2 and 3 
Examples of Statements related to payments for the treatment of study-related injury and their implications
Statement Implications "While providing appropriate medical treatment for study-related injury, there is no commitment to provide you with free medical treatment for such an injury or illness unless the study sponsor, at its discretion approves payment for such medical treatment, over and above any amounts paid by your health insurance."
• No free treatment even when the injury is study-related.
• Discretion rests solely with the sponsor.
"Compensation for the treatment(s) will be made available to the subject in the event of a trial-related injury. The sponsor will Þ nancially cover any injury caused to you related to XYZ-1234 during the study period."
• Participants in control arm and injuries related to study-procedures not included in compensation.
"If you follow the directions of the doctors and you are physically injured because of any substance or procedure properly given to you under the plan of this study, the medical expenses for the treatment of that injury would be borne by the sponsor."
• No payment for treatment of injury if substance or procedure not given/done properly by the investigator(s).
"What about insurance and compensation? You will not be paid any kind of compensation in cash. But, in case of any study-related injury; you will be treated for that injury by the insurance policy done by sponsor."
• Details of insurance policy not revealed to the participant. Exclusions in the policy could harm participants' interests.
"I understand that xyz is a fairly safe drug. It may cause rash, photosensitivity reactions, peeling of the skin (exfoliative dermatitis) or severe drug reaction called Stevens-Johnson syndrome. I will have to report to the doctor, if I feel discomfort on taking that medicine. The doctor will take appropriate measures to see that my health is safeguarded."
• No mention of free treatment or whether expenses on treatment of study-related injury would be reimbursed.
"The sponsor will pay for the medical costs if it has been determined that your child qualiÞ es for enrollment, if you have followed instructions and the bad effects came due to your child's participation in the study."
• No payment for treatment related injury, if there is wrongful enrollment by the investigator.
"Reimbursement shall be made by the funder for the study, for reasonable and necessary medical expenses incurred by a study participant as a direct result of the treatment of adverse reactions from the drugs used in the study in accordance with the protocol, provided such expenses are not covered by participant's medical or hospital insurance coverage, and are in no way attributable to the negligence or misconduct of any agent or employee of XYZ Hospital."
• Too many caveats • Injury related to study procedures (other than administration of drugs) not covered.
"What if something goes wrong?
During the course of the trial, if anything goes wrong or you experience any serious medical event, please let your doctor know immediately. You will be provided with utmost medical care including hospital admission. If you are harmed due to someone's negligence, then you may have grounds for legal action."
• Who will bear the cost of treatment has not been stated.
• Indicates that no compensation will be provided if the investigator or his team has erred. The participant has to take recourse to costly and time-consuming legal processes.
"The IUD may rarely cause perforation of uterus. If you have any such complaint during use, you will be provided treatment/counseling. However, if there is any life-threatening medical condition, you will report to the hospital and will be managed as per normal hospital practices. There is no monetary compensation for enrollment, follow-up or in the event of any side-effect."
• 'Normal hospital practices' not explained.
• No compensation for study-related injury.
If the sponsor were unwilling, the participants cannot be left to fend for themselves and there should be some mechanism for providing compensation and free treatment for injury, either through the investigator or his/her institution. It is noteworthy that of the 129 policies of 102 academic medical centers in the USA, 51% made no provision for providing free care and 8% provided only free emergency or INDIAN JOURNAL OF MEDICAL SCIENCES immediate care. As many as 19% of the policies did not provide publicly accessible information in this regard. [5] The data was collected from only two ECs situated in Mumbai. It may be argued that this may not be representative of the situation in the whole country. It may be clarified here that the ECRHS received proposals from several pharmaceutical companies and that the Independent EC received research proposals from several other cities and towns in India.
The Þ ndings of the study provide an insight into the existing lacunae and have helped identify the training needs. The policy regarding ethical issues is generally enunciated in the Ethics section of the Protocol. However, this protocol is not generally accessible to prospective participants, and in any case, the ICD is expected to reß ect and clarify the policy stated in the Protocol. Hence, these documents were studied in preference to the Protocol. Table 3 : Statements related to compensation for study-related injury and their implications
INFORMED CONSENT DOCUMENTS SUBMITTED FOR INITIAL REVIEW

Statement Implications
"We would not be bound by these guidelines to pay compensation where: the injury resulted from a drug or procedure outside the trial protocol or the study protocol was not followed."
• There is no compensation, if the protocol was not followed by the investigator.
"The 'sponsor' will reimburse the cost of extra unanticipated tests, treatments, hospitalizations of patients required as a result of adverse events which the 'sponsor' determines with reasonable medical certainty, to have resulted from substances dispensed or administered properly and in accordance with study protocol."
• The research participant will need to spend on tests without any certainty of being reimbursed of those expenses.
• No reimbursement even if injury has occurred due to errors committed by investigation team in administering substances or in following the protocol "The 'sponsor' has taken out an insurance policy to cover compensation for any personal injury resulting from the participation in this study, provided such injury is not due to fault or negligence."
• It is not clear if the participant would be eligible for compensation if the investigator has committed fault or negligence.
"The sponsor has insurance for covering study related expenses. Study-related injury will be compensated based on applicable British Guidelines."
• Exact nature of what the insurance covers is not provided.
• The British Guidelines have not been identiÞ ed and details are not provided for the prospective participant to taken an informed decision. • Organize training programs to discuss the issue of providing treatment and compensation for research-related injury with investigators and sponsors: Current thinking and guidelines.
• Have a well-thought out policy on what the minimal expectations would be regarding providing treatment and compensation when a research participant suffers trial-related injury.
• Have a mechanism in place to handle appeals and disputes and to decide on the quantum of compensation.
• Provide a template for ICD:
Clearly differentiate between compensation for participation, treatment for trial-related injury, and compensation for trial-related injury. Treatment for trial-related injury: Have an arrangement to provide emergency treatment free of cost, provide free treatment or reimburse expenses incurred on treatment of trial-related injury, delineate steps that the participant should take if anything untoward occurs, do away with caveats related to using personal insurance or government program(s). Do away with restrictions such as treatment/compensation being available only for the trial drug arm, only for substances administered (not for trial-related procedures), only if the study is properly conducted as per protocol, and only if eligibility has been properly assessed.
In case of error/negligence on part of the investigator, there should be some mechanism for providing free treatment and compensation for a trial-related injury, if the sponsor is unwilling to do so.
• Train EC members in sifting ICDs for statements providing inadequate protection.
The EC members need to be very vigilant and ensure that these statements are: i) in conformity with the letter and spirit of national and international guidelines, ii) are not ambivalent or ambiguous, and iii) fully protect the interests of research participants. In addition, the ECs should take the initiative to inform and educate investigators and stakeholders from industry about current opinions and expectations. Some broad suggestions are provided in Table 4 that would help investigators and sponsors submit ICDs that provide adequate protection to participants who may suffer from trial-related injury.
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